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Abstract
Inducible Co-stimulator (ICOS) plays a critical role in mediating T cell differentiation and function and is considered a key
player in balancing T effector and T regulatory (Treg) cell responses. Here we show that activation of the ICOS signalling
pathway during acute influenza A virus (IAV) infection by application of an agonistic ICOS antibody reduced the frequency
of CD8+ T cells in the respiratory tract of IAV infected animals and delayed pathogen elimination. In line with this, immune-
mediated influenza pneumonia was significantly ameliorated in mice that received ICOS agonist as indicated by significantly
reduced alveolar infiltrations and bronchointerstitial pneumonia, while at the same time virus-related pathology remained
unaffected. Importantly, ICOS agonist treatment resulted in expansion of CD4+Foxp3+ Tregs in IAV infected mice, which was
associated with elevated levels of the immunosuppressive cytokine IL-10 in the alveolar space. Together, our findings
suggest a prominent role of ICOS signaling during acute IAV infection by increasing the Treg/CD8
+ T cell ratio with beneficial
outcome on immune-mediated pneumonia and underline the suitability of ICOS as potential therapeutic target for immune
intervention in those infectious conditions characterized by strong immunopathology rather than virus-mediated
cytopathic effects.
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Introduction
Inducible co-stimulator (ICOS) is a T cell co-stimulatory
molecule that belongs to the CD28 Immunoglobulin (Ig)
superfamily [1]. It is primarily expressed on activated T cells
and mediates its immunological functions by binding to its ligand
ICOS-L [2], [3]. ICOS/ICOS-L interaction provides a co-
stimulatory signal to the T cells resulting in the amplification of
T cell activation and enhanced proliferation as well as cytokine
secretion [4]. ICOS signaling was shown to play an essential role
for the differentiation of T cells into Th1 and Th2 cells following
antigen-specific activation [5–8] and a recent study emphasizes
that ICOS plays an important role also in promoting Th17
responses [9–11]. Germinal center formation is impaired in mice
lacking ICOS and ICOS plays a critical role in co-stimulating
humoral immune responses [12], [13]. So far, ICOS-mediated co-
stimulation has been predominantly reported to play a role in
CD4+ T helper cell subsets, but there is accumulating evidence for
an effect of ICOS also on CD8+ T cells [14–16].
Next to its multifaceted role in the initiation of adaptive immune
responses, ICOS has also been described to be crucially involved
in the regulation of adaptive immunity. While ICOS was originally
shown to enhance T cell proliferation, differentiation and
induction of certain effector cytokines [17], ICOS/ICOSL
interaction was more recently shown to specifically super-induce
the synthesis of the anti-inflammatory cytokine IL-10 [18], [19].
Interestingly, thymus-derived regulatory T cells (Treg) can be
subdivided according to the expression of ICOS, with ICOS+-
FOXP3+ Treg releasing both, IL-10 to suppress dendritic cell
function and TGF-b to suppress T cell function, in contrast to
ICOS2Foxp3+ Treg secreting TGF-b only [20], [21]. Blockade or
absence of ICOS inhibited the production of IL-10 and abrogated
the inhibitory function of Tregs [22], [23]. As demonstrated in a
murine model for autoimmune diabetes, disturbance of the
balance between T effector (Teff) and Treg cells by interference
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with the ICOS signaling pathway led to the conversion of early
insulitis to diabetes indicating that Treg prevented pancreatic islet
destruction in an ICOS-dependent mechanism [24]. In line with
this, a defect in the induction of Foxp3 and ICOS expression was
observed in newly diagnosed type 1 diabetic children [25]. Of
note, a crucial role of ICOS has also been reported for the
generation and suppressive function of Treg conveying respiratory
tolerance in a mouse model of allergic asthma [26]. Taken
together, these existing reports clearly indicate that ICOS co-
stimulates distinct effector and regulatory functions in T cells,
thereby critically affecting the outcome of adaptive immune
responses. The proposed function of ICOS to bias T cell responses
in vivo makes this molecule a promising target for therapeutic
intervention in numerous inflammatory and infectious conditions.
Studies on the specific role of ICOS in immunity to bacterial,
viral or parasite infection have been greatly facilitated by the
availability of mice lacking ICOS or using systemic delivery of
blocking antibodies and revealed that the absence or blockade of
ICOS leads to either unaffected of reduced CD4+ or CD8+ T cell
responses [5], [14], [27–30]. For example, during Mycobacterium
tuberculosis (Mtb) infection, it has been demonstrated that ICOS
deficiency differentially affects CD4+ and CD8+ T cell subsets,
ultimately resulting in improved protection in the spleen but not
the lungs during later stages of Mtb infection [31]. While in this
study ICOS deficiency resulted in a reduced Mtb-specific CD8+ T
cell response, ICOS2/2 mice displayed no defect in the initial
pathogen-specific CD8+ T cell expansion or cytotoxic effector
function following influenza A virus (IAV) infection. However,
ICOS was important in maintaining CD8+ T cell numbers in the
late phase of the primary response [32]. In another study, on the
role of ICOS co-stimulation for the outcome of IAV infection that
utilized antibody-mediated ICOS inhibition, a marked reduction
of cytokine-secreting CD4+ and CD8+ T cells was observed in the
lung. This was associated with reduced pulmonary T cell
inflammation and elevated lung viral titers but at the same time
increased soluble inflammatory mediators were detected in the
lung [30]. Together, these examples suggest that selective blockade
of ICOS signaling biases T cell responses in vivo with implications
for the course of infection.
To our knowledge, in vivo studies on the potential role of ICOS
in T cell activation, differentiation and function have so far been
performed in either ICOS2/2 mice or by antibody-mediated
ICOS blockade. In contrast to this, in the present study we
combined IAV infection with systemic delivery of a stimulating
anti-ICOS antibody to super-induce ICOS signaling in T cells.
Our studies revealed that ICOS agonist treatment during acute
IAV infection resulted in reduced CD8+ T cell levels in the
respiratory tract while at the same time the frequency of peripheral
CD4+Foxp3+ Tregs was increased. Changes in the Treg to CD8
+ T
cell ratio were associated with delayed viral clearance, increased
IL-10 concentration in the bronchoalveolar space and a signifi-
cantly attenuated immunopathology in the lung of IAV infected
mice. Together, these data suggest that ICOS agonist treatment
during acute IAV infection has a beneficial effect on immune-
mediated influenza pneumonia, most likely caused by an increased
Treg/CD8
+ T cell ratio, supporting the idea that ICOS can be
considered a promising molecular target for future development of
specific in vivo immune intervention strategies.
Materials and Methods
Mice, ICOS antibodies and experimental procedure
All animal experiments were approved by the Niedersa¨chsisches
Landesamt fu¨r Verbraucherschutz und Lebensmittelsicherheit.
Eight to ten week old female BALB/c mice were obtained from
Harlan Winkelmann (Rossdorf, Germany) and were used for this
study. Mice were maintained under specific pathogen-free
conditions in the animal facility at the Helmholtz Centre for
Infection Research, Braunschweig, Germany. For sub-lethal
intranasal influenza infection mice were anaesthetized by Keta-
mine/Rompun (dose of 0.1 ml/10 g of mice) and a volume of
25 ml of the PR/8/34 (H1N1) virus strain containing the
appropriate concentration (a dose lethal to 50% of inoculated
BALB/c mice (MLD50)) of virus was administered onto the
nostrils. Following infection, mice were divided into two experi-
mental groups: the first group received 200 mg of anti-ICOS
agonist antibody on day 1 and 100 mg ICOS agonist on day 5
post-infection, whereas the control group received the same doses
of hamster IgG isotype control antibody. Alternatively, in one
experimental setting, two additional groups were included that
received anti-ICOS antagonist antibodies and rat IgG isotype
controls, respectively. Mice were sacrificed and analyzed during
the peak phase of adaptive immunity (day 7–9), as indicated in the
figure legends. All experiments were performed in accordance to
the institutional and national guidelines. Anti-ICOS agonist
antibody (clone C398.4A) was produced and purified as described
before [33]. Of note, in order to exclude the possibility that
potential effects of in vivo anti-ICOS agonist treatment might be a
result from blocking ICOS-ICOS-L interaction rather than from
agonistic signaling following ICOS agonist binding to T cells,
activated splenic T cells were pre-incubated with ICOSL-Fc
followed by C398.4A staining. Subsequent FACS analysis revealed
only minor blockade of C398.4A binding by soluble ICOS-L pre-
incubation (Figure S1). In addition, we could clearly rule out the
possibility that in vivo ICOS agonist treatment results in depletion
of ICOS+ T cells (Figure S2). Polyclonal hamster IgG isotype
control antibody, anti-ICOS antagonist antibody (clone 17 G9)
and the rat IgG2b isotype control antibody were purchased from
Bio-X-cell, USA.
Lymphocyte isolation and serum preparation
Mice were sacrificed and lungs, bronchial lymph nodes (BLN)
and spleens were excised in order to obtain single cell suspensions,
for further usage. Lungs were perfused prior to excision and
lymphocytes were isolated by enzymatic tissue digestion and
density gradient centrifugation as described before [34]. Cells from
BLN were prepared by smashing them through 70 mm cell-
strainers. Single cell suspensions were then washed and re-
suspended in FACS buffer (phosphate buffer saline (PBS), 2% fetal
calf serums (FCS), 0.5 M EDTA). Splenocytes were processed by
flushing the spleen with ACK (ammonium chloride potassium) red
cell lysis buffer and passing the cells through 70 mm cell strainers.
Intermittent washing and centrifugation (1200 rpm) was per-
formed at 4uC. The obtained single cell suspensions were re-
suspended in FACS buffer. Cells from the bronchoalveolar space
were isolated by flushing the lungs twice with 1 ml of PBS. Cells
were then pooled and centrifuged at 2000 rpm for 10 minutes. In
case lavage fluid was collected for further analysis, centrifugation
of the collected supernatants was increased to 10,000 rpm for
10 minutes and stored at 270uC until usage. Cardiac puncture
was done to collect blood for serum preparation. The blood
samples were incubated at 37uC for 30 minutes and then cooled to
4uC for 30 minutes. These samples were then centrifuged at 2000
rpm for 10 minutes and sera were collected and stored at 220uC
until usage.
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Flow cytometry
Single cell suspensions prepared from lungs, BLNs, spleens and
bronchoalveolar lavage were stained with the indicated combina-
tions of Alexa Fluor 780-conjugated anti-CD4 (RM4–5,
eBioscience), anti-CD8-PEcy7 (53-6.7, BioLegend), biotinylated
anti-ICOS (7E.17G9, BioLegend), biotinylated anti-CD43 (1B11,
BioLegend) and APC/cy7streptavidin (BioLegend). For intracel-
lular cytokine staining, cells were stimulated for 2 hours with
phorbol 12-myristate 13-acetate (PMA) (0.1 mg/ml, Cat#p1585,
Sigma) and ionomycin (1 mg/ml, Cat#I0634, Sigma) and with
golgi stop (Brefeldin) (5 ml/ml, Cat#B7651, Sigma) for 2 hours,
followed by permeabilization with NP-40 (igepal CA-630, Sigma)
and staining with anti-IFNc-APC (XMG1.2, BioLegend). Intra-
cellular FoxP3 expression was determined using the FoxP3
staining buffer kit (FJK-16s, eBioscience) according to the
manufacturer’s recommendations. For apoptosis assay, Annexin/
7AAD staining was performed as described previously [35]. Flow
cytometric analysis was performed using a FACSCanto or
LSRFortessa (BD Biosciences) running with THE FACSDiva
software (version 6.1.3) (BD Biosciences). Analysis was performed
using FlowJo version 9.5.3 (Tree star, Inc.).
In vivo cytotoxic T lymphocyte (CTL) assay
Target cells (splenocytes) loaded with virus-antigen were
adoptively transferred into IAV infected mice on day 9 following
infection. For each recipient, 26107 splenocytes were loaded with
IAV nucleoprotein (NP) peptide antigen (TYQRTRALV), HZI
Peptide Synthesis Platform and 26107 cells served as control.
Antigen-loaded cells were stained with 2.5 mM carboxyfluores-
ceine succinimidyl ester (CFSE, Molecular Probes) (CFSEhigh)
while unloaded control cells were stained with 0.25 mM CFSE
(CFSElow). Cells were pooled and intravenously injected into
recipients. These were sacrificed 4 hrs after transfer and the
splenocytes were isolated and analysed by flow-cytometry. CFSE-
positive lymphocytes were divided into CFSElow and CFSEhigh
populations and percent lysis of target cells was calculated (r = (%
CFSElow/% CFSEhigh); % lysis = (1–(runinfected/rinfected)6100).
RNA isolation and Real time PCR
Lungs were homogenized in TriFastFL reagent (PeqLab). RNA
was extracted by addition of 1-Br-3-Cl-Propane (Merck), purified
by precipitation and treated with DNase (Ambion) prior to reverse
transcription to cDNA (M-MLV Reverse Transcriptase, Invitro-
gen). RNA concentration was determined using a Nano Drop
(ND-1000 spectrometer). Concentration of 2.5 ng of RNA was
utilized for reverse transcription into cDNA. cDNA concentration
was adjusted to 50 ng/ml for virus quantification using real-time
PCR with primers specific for the viral nucleoprotein (NP) (59-
GAG GGG TGA GAA TGG ACG AAA AAC and 39-CAG GCA
GGC AGG CAG GAC TT) and a reference plasmid carrying the
NP-sequence (pVI-PmH5-PR8-NP; pro-vided by G. Sutter,
Munich, Germany) to obtain a CT-value/NP copy number
standard. This standard was used to quantify NP copy numbers in
the samples. All PCR analyses were performed in triplicates.
Enzyme Linked Immuno-Sorbent Assay (ELISA)
BALF samples were collected by flushing the lungs with PBS
followed by centrifugation as described above and were stored at
270uC until usage. IL-6, IFN-c, TNF-a, and IL-10 concentrations
in BALF were quantified by standard ELISA (BioLegend)
according to the manufacturers instruction. All analyses were
run in duplicates.
High Performance Liquid Chromotography (HPLC)
Tryptophan and kynurenine concentrations in serum and BALF
samples were determined by reversed-phase HPLC as described
earlier [36]. Specimens were deproteinized with trichloroacetic
acid and were separated on reversed phase C18 material using
0.015 mol/l potassium phosphate buffers (pH 6.4). Tryptophan
was monitored by means of its native fluorescence (Varian ProStar
360, Palo Alto, CA) at 285 nm excitation and 360 nm emission
wavelengths. Kynurenine was detected by ultraviolet absorption
(Shimadzu SPD-6A, Korneuburg, Austria) at 365 nm wavelength
in the same chromatographic run. Finally, kynurenine/tryptophan
(kyn/trp) was calculated as an estimate of IDO activity [37].
Histology
Whole lung sample were fixed in neutrally buffered 4%
formaldehyde. Cross sections of the lungs were made with
approximate 2 mm thickness. Tissue samples were removed from
the fixatives and routinely paraffin embedded. Tissue sections
(2 mm) of the paraffin-embedded tissue samples were cut and
stained with hematoxylin and eosin (HE).
In vitro Apoptosis Assay
Splenocytes from BALB/c mice were processed and used for
this assay. The 96 well plate was coated with anti-CD3 antibodies
(0.75 mg/ml) and incubated at 37uC for one hour. The plate was
then washed twice with PBS. Equal numbers of splenocytes
(56105 cells/well) were added along with different concentration
of anti-ICOS agonist antibodies (0.01, 0.1, 1, 5 mg/well) and
incubated (at 37uC) for 3 days. Splenocytes without anti-ICOS
antibodies acted as activated control and splenocytes without any
antibodies acted as unactivated control. All the samples were run
in triplicates. The results were obtained with FACS acquisition as
described [35].
Statistics
Statistics were performed applying non-parametric Mann-
Whitney test or unbiased unpaired t test as indicated in the figure
legends using Graph Pad Prism 5.02 (Graph Pad Software, La
Jolla). For the statistical analysis of IDO enzymatic activity, the
Statistical Package for the Social Sciences (SPSS), Predictive
Analytics Software Statistics (PASW Statistics 18, Chicago, IL,
USA) was used. A p-value of ,0.05 was considered significant
(*p#0.05; **p#0.01; ***p#0.001).
Results
ICOS agonist treatment does not affect the overall course
of influenza infection in mice
To study the impact of in vivo ICOS agonist treatment on the
course of influenza infection, we used the experimental set-up
summarized in Figure 1A. Female BALB/c mice were infected
intranasal with a sub-lethal dose of influenza virus (IAV) followed
by systemic ICOS agonist treatment. FACS analysis revealed
rapid induction of ICOS expression on CD4+ and CD8+ T cells
early after influenza infection (Figure S3). Taking further into
account a limited half-life of the ICOS agonist antibody in vivo we
performed ICOS agonist treatment on day 1 and 5 post infection
to ensure its effect on T cells during the early and late phase of
infection. Body weight loss as an indicator for disease severity was
monitored, over the depicted time period of 2 weeks (Figure 1B).
Apart from a mild delay in weight gain in the ICOS agonist
treated group during the recovery phase, no significant differences
in body weight loss was observed between the groups indicating
ICOS Stimulation Attenuates Influenza Pneumonia
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that ICOS agonist treatment during the acute phase of IAV
infection does not affect the overall course of the infectious disease.
ICOS agonist treatment reduces the CD8+ T cells
frequency in respiratory tract of IAV infected mice
Since ICOS is rapidly induced on activated CD4+ and CD8+ T
cells following IAV infection (Figure S3 and [36]), thereby
making them targets for ICOS agonist binding, we first analyzed
whether ICOS agonist treatment of IAV infected mice would
affect the composition of the polyclonal T cell pool. Indeed, FACS
analysis during the peak phase of adaptive immunity revealed a
significantly reduced percentage of CD8+ T cells in the lung
parenchyma and bronchoalveolar space (Figure 2A), but not in
the BLN and spleen (data not shown), of ICOS agonist treated
mice compared to the isotype control treated group. Moreover,
the frequency of effector CD8+CD43+IFN-c+ T effector cells in
BAL and spleen was slightly but not significantly decreased on day
7 and 9 post infection (data not shown). Interestingly, ICOS
agonist treatment had no effect on the polyclonal CD4+ T cell pool
(Figure 2A and data not shown).
To determine whether reduced pulmonary CD8+ T cell levels in
ICOS agonist treated animals may be attributed to an enhanced
apoptosis induction in activated T cells, we performed in vitro
apoptosis assays. For this purpose, splenic T cells were stimulated
Figure 1. Schematic representation of the experimental procedure. (A) BALB/c mice were infected intranasal with a sub-lethal dose of IAV on
day 0. Intraperitoneal injection of ICOS agonistic antibody or hamster IgG isotype control antibody was performed on day 1 (200 mg/mouse) and day
5 (100 mg/mouse) post infection followed by body weight monitoring for 2 weeks. For functional analyses, mice were sacrificed and analyzed
between day 7 and 9 post infection, i.e. during the peak of adaptive immunity. (B) Mice were IAV infected and treated with ICOS agonist (n = 5) or PBS
(n = 5) as described above and body weight was monitored over a time period of two weeks post IAV infection (non-parametric Mann-Whitney test
was used to observe weight difference between two groups).
doi:10.1371/journal.pone.0100970.g001
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with a-CD3 and cultivated in the presence or absence of ICOS
agonist. Indeed, annexin V staining revealed an increased
percentage of apoptotic CD8+ T cells in ICOS agonist treated
cells compared to CD8+ T cells stimulated in the absence of ICOS
agonist (Figure 2B). The opposite was found for CD4+ T cells
which appeared to even be protected from apoptosis induction
following TCR stimulation in the presence of ICOS agonist
(Figure 2C). Together, these data demonstrate that ICOS agonist
treatment during acute IAV infection reduces CD8+ T cell levels
in the respiratory tract, which may be, at least in part, due to the
induction of apoptosis in activated CD8+ T cells.
ICOS agonist treatment results in delayed pathogen
elimination from the infected lung
To assess whether the ICOS agonist-mediated reduction in
CD8+ T effector cells would result in impaired IAV-specific
cytotoxicity, in vivo CTL assays were performed based on the
adoptive transfer of IAV nucleoprotein (NP) peptide loaded
splenocytes into ICOS agonist treated and control mice on day 9
post infection. Indeed, we observed a slightly reduced lysis of
peptide-pulsed APC in the ICOS agonist treated group, although
this did not reach the level of statistical significance (Figure 3A).
Since viral clearance is largely dependent on CTL activity, we next
analyzed whether reduced CD8+ T effector cell levels and
cytotoxic activity would affect pathogen elimination in the lung.
For this purpose, viral load was determined on day 7, 8, and 9 post
infection. Whereas control animals had cleared the virus by day 9
post infection, ICOS agonist treated mice displayed higher virus
titers at all times analyzed and showed a delay in virus elimination
(Figure 3B). Notably, delayed viral clearance in ICOS agonist
treated mice was as well evident when compared to mice treated
with ICOS antagonist antibody, which transiently blocks ICOS
signaling in T cells (data not shown), further corroborating that the
observed effect can be attributed to the agonistic action of ICOS.
ICOS agonist treatment attenuates immune-mediated
influenza pneumonia
We next investigated whether ICOS agonist treatment would
have an effect on the severity of lung inflammation. Histological
analysis performed on day 7 and 9 post infection revealed the
typical signs of influenza pneumonia with multifocal, lymphocytic,
bronchointerstitial pneumonia and alveolar infiltration with
Figure 2. ICOS agonist treatment reduces the frequency of CD8+ T cells but does not affect the polyclonal CD4+ T cell compartment.
IAV infected BALB/c mice were treated with ICOS agonist or hamster IgG isotype (control antibodies) as depicted in Figure 1A. On day 7–9 post
infection the percentage of CD8+ in BAL (day 7, pooled data from two independent experiments) and lung (day 8) as well as CD4+ T cells in lung (day
9) was determined by flow cytometry. The dots in all experiments represent data from individual mice (A). In vitro apoptosis assays were performed,
as described in materials and methods, followed by annexin-V staining on live T cells and subsequent flow cytometric analysis. Dot plot graphs
indicate percentages of apoptotic CD8+ and CD4+ T cells (mean of triplicate wells) plotted against increasing concentration of ICOS agonist antibody
added to the culture. CD3 alone (mean of triplicate wells) represents that cells were stimulated by anti-CD3 treatment, in the absence of ICOS agonist;
untreated (mean of duplicate wells) represents that cells were neither anti-CD3 stimulated nor treated with ICOS agonist. Column statistics were
performed for the apoptosis assay (the data is expressed by mean/SEM) (B and C).
doi:10.1371/journal.pone.0100970.g002
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mainly lymphocytes, fewer neutrophils and macrophages in both
experimental groups (Figure 4A). However, in ICOS agonist
treated animals, immune-mediated inflammation was ameliorated
as indicated by significantly reduced bronchointerstitial and
alveolar infiltrations, as well as a decrease in the extent of lung
tissue affected by the inflammation in comparison to control mice
on day 7 post infection. In contrast, no differences were observed
for virus-related epithelial necrosis (Figure 4B). Moreover, we did
not observe any histological differences between the groups on day
9 post infection (Figure 4C). Next to histological evaluations of
the lung tissue, we quantified pro-inflammatory cytokine levels in
bronchoalveolar lavage fluid (BALF) collected from ICOS agonist
treated and control mice. As depicted in (Figure 4D) BALF
concentrations of IL-6, IFN-c and TNF-a in IAV infected animals
were not affected by ICOS agonist treatment. In conclusion,
histopathological scoring revealed a positive effect of ICOS agonist
treatment on immune-mediated pneumonia and this beneficial
effect is only evident at day 7 but not at day 9 post infection.
ICOS agonist treatment increases the frequency of
CD4+Foxp3+Tregs and BALF levels of IL-10 cytokine
Next to being induced on activated T cells, ICOS is also
expressed on CD4+ Tregs which are known to play a key role in
balancing aggressive immune responses, thereby preventing
overwhelming immunopathology in infected tissues. To test
whether attenuation of lung inflammation would be accompanied
with the expansion of Tregs upon ICOS agonist treatment, the
frequency of CD4+Foxp3+ Tregs during the peak phase of adaptive
immunity was compared in mice treated with ICOS agonist or
control antibody. Interestingly, we indeed found significantly
increased percentages of Tregs in BLN and spleens, as well as
slightly augmented Treg levels in the lung of ICOS agonist treated
animals on day 7 or 8, but not on day 9 post infection (Figure 5A).
In line with this, we observed significantly increased concentra-
tions of the anti-inflammatory cytokine IL-10 in the bronchoal-
veolar space of ICOS agonist treated mice on day 8 post infection
(Figure 5B) as well as slightly elevated BALF and serum kyn/trp
which indicates accelerated tryptophan breakdown that is most
probably due to activity of the immune regulatory enzyme
indoleamine 2,3-dioxygenase (IDO) (Figure 5C). Together, our
data suggest a beneficial effect of ICOS agonist treatment during
acute IAV infection on the severity of lung inflammation by
decreasing the frequency of CD8+ T cells but at the same time
supporting the expansion of Tregs.
Discussion and Conclusion
While previous studies on the specific function of ICOS
signaling in inflammatory and infectious conditions have been
performed in mice lacking ICOS or by using antibody-mediated
blockade of ICOS function, to our knowledge this is the first report
on the utilization of a stimulating ICOS antibody for in-vivo
immune modulation. Based on results obtained from previous
infection studies in the absence of ICOS [5], [14], [15], [27–31],
we hypothesized that a specific stimulation of ICOS during an
acute IAV infection should affect the induction and/or regulation
Figure 3. Delayed virus clearance as a consequence of ICOS agonist treatment during acute IAV infection in mice. (A) BALB/c mice
were infected and treated with ICOS agonist or control antibody as depicted in Figure 1A. On day 9 post infection, influenza-specific in vivo CTL
assays were performed, as described in materials and methods. Dot plots represent percentage specific lysis of peptide-loaded APCs by IAV-specific
cytotoxic T cells in ICOS agonist and isotype control treated mice. Every dot represents data obtained for an individual mouse. (B) BALB/c mice were
treated as described before with ICOS agonist antibodies and the respective isotype control antibodies. On day 7, 8 and 9 post IAV infection mice
were sacrificed and NP copy numbers as an indicator for viral load was determined in the lung by quantitative RT-PCR. Dots represent data obtained
for individual mice. The data were pooled from two independent experiments. Statistical analysis was done by non-parametric Mann-Whitney test.
doi:10.1371/journal.pone.0100970.g003
ICOS Stimulation Attenuates Influenza Pneumonia
PLOS ONE | www.plosone.org 6 July 2014 | Volume 9 | Issue 7 | e100970
Figure 4. Attenuated immune-mediated pneumonia in ICOS agonist treated mice. BALB/c mice were IAV infected and treated with ICOS
agonist and isotype control antibody as depicted in Figure 1A. On day 7 and 9 post infection lungs were collected and subjected to histological
examination. (A) A – ICOS agonist, day 7: bronchiointerstitial pneumonia, grade 1, lymphocytic and neutrophilic; alveolar infiltration, grade 1, with
lymphocytes, neutrophils and fewer alveolar histiocytes; B – isotype control, day 7: bronchiointerstitial pneumonia, grade 2, lymphocytic, with
scattered neutrophils; alveolar infiltration, grade 1, with lymphocytes, fewer neutrophils and alveolar histiocytes; C – ICOS agonist, day 9:
bronchiointerstitial pneumonia, grade 2, lymphocytic, with scattered neutrophils; alveolar infiltration, grade 2, with lymphocytes, fewer neutrophils
and alveolar histiocytes; D – isotype control, day 9: bronchiointerstitial pneumonia, grade 2.5, lymphocytic, with scattered neutrophils; alveolar
infiltration grade 2.5, with lymphocytes, fewer neutrophils and alveolar histiocytes; bronchial epithelial necrosis, grade 2; E – ICOS agonist, day 7:
bronchointerstitial pneumonia, grade 1; F – isotype control, day 7: bronchointerstitial pneumonia, grade 3; G- ICOS agonist, day 7: Alveolar infiltration,
grade 1; H - isotype control, day 7: Alveolar infiltration, grade 3; I - ICOS agonist, day 7: Necrosis of bronchial epithelium, grade 1; J – isotype control,
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of virus-specific T cell responses with potential implications for
pathogen elimination and immune-mediated pathology.
We first characterized the overall impact of ICOS agonist on
the composition of the polyclonal T cell pool during the peak
phase of adaptive immunity. While no effect of ICOS agonist
treatment was observed for the frequency of respiratory CD4+ T
cells, we found significantly decreased levels of CD8+ T cells in the
lung and BALF as well as slightly reduced frequencies of
CD43+IFN-c+ CD8+ Teff (Figure 2 and data not shown). This
was somehow unexpected since ICOS/ICOS-L interaction has
been demonstrated before in a tumor model to improve priming of
naı¨ve CD8+ T cells [38], [39]. Moreover, a drop in CD8+ (and
CD4+) T cells was also observed in IAV infected mice treated with
an antibody blocking ICOS [30]. Another study using IAV
infection in ICOS2/2 mice revealed no differences in primary
expansion of virus-specific CD8+ T cells [32]. Very importantly, in
contrast to these studies focusing on CD8+ T cell expansion in IAV
infected mice in the absence of functional ICOS signaling, we
day 7: Necrosis of bronchial epithelium: grade 2. (B and C) Inflammation score for alveolar infiltration, broncho-interstitial pneumonia, affected lung
tissue and bronchiola & alveolar necrosis on day 7 and 9, respectively, post IAV infection. 1 =mild; 1.5 =mild to moderate; 2 =moderate;
2.5 =moderate to severe; 3 = severe; %= area of affected tissue; n = 5 mice in the ICOS agonist treated group, n = 3 mice in the isotype treated group.
(D) Bronchoalveolar lavage fluid was collected on day 8 post IAV infection and concentration of IL-6, IFN-c (data obtained were pooled from two
independent experiments) and TNF-a was determined by ELISA. Dots represent data obtained for individual mice. Statistical analysis was done by
non-parametric Mann-Whitney test.
doi:10.1371/journal.pone.0100970.g004
Figure 5. Increased frequency of Tregs and elevated IL-10 levels in mice treated with ICOS agonist during acute IAV infection. (A)
Mice were treated as described in Figure 1A. On day 7, 8 and 9 post infection, mice were sacrificed and CD4+ T cells isolated from the lung (left panel:
day 8 p.i.; right panel: day 9 p.i.), BLN (left panel: day 7 p.i.; right panel: day 9 p.i.) (pooled data from two independent experiments) and spleen (left
panel: day 8 p.i.; right panel day 9 p.i.) (pooled data from two independent experiments) were analyzed for the intracellular expression of the Treg-
specific transcription factor Foxp3. (B) Bronchoalveolar lavage fluid of mice infected with IAV and treated with ICOS agonist or control antibody was
collected on day 8 post infection and IL-10 concentration was determined by ELISA. The data obtained were pooled from two independent
experiments (C) In addition, tryptophan (trp) and kynurenine (kyn) concentrations were determined in serum samples (pooled data from two
independent experiments) and bronchoalveolar lavage fluid by reversed-phase HPLC technology. IDO enzymatic activity is estimated as kyn/trp ratio.
Dots represent data obtained for individual mice. Statistical analysis was done by non-parametric Mann-Whitney test.
doi:10.1371/journal.pone.0100970.g005
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super-stimulated ICOS signaling. Reduced CD8+ T cell levels in
ICOS agonist treated animals may be due to the existence of a
negative feedback loop controlling excessive division and differ-
entiation of primed CD8+ T cell or may be due to increased cell
death specifically induced in CD8+ T cells. The former concept is
supported by the observation that ICOS stimulation during
ongoing infection supports the expansion of Tregs and the
establishment of an immunosuppressive environment. The latter
concept is supported by our data obtained in in-vitro apoptosis
assays revealing that T cell stimulation in the presence of ICOS
agonist predisposes CD8+ (but not CD4+) T cells for death by
apoptosis (Figure 2). This is well in line with another study that
demonstrated differential effects of ICOS on CD4+ and CD8+ T
cells with an increased ability of ICOS2/2 CD8+ T cells to induce
Graft-versus-Host Disease (GvHD) as a result of enhanced survival
and expansion of those cells [40].
Since CD8+ T cells are pivotal for the efficient elimination of
IAV from the lung [41], reduced CD8+ T cell levels should give
rise to failures in antiviral immunity and pathogen clearance. This
was indeed what we observed in our study. An earlier study
reported [32] that ICOS deficient mice show normal IAV-specific
CTL responses compared to mice sufficient for ICOS signaling,
ICOS agonist treated animals showed a slightly reduced tendency
for IAV-specific cytotoxic T cell function (Figure 3), which
correlated with delayed pathogen elimination from the respiratory
tract. Whereas control animals cleared the virus within 9 days post
infection, virus was still detectable in the lungs of mice treated with
agonistic ICOS antibody at this time (Figure 3). Reduced CD8+
T cell frequencies and CTL activity together with delayed
pathogen elimination are very well in line with the finding that
ICOS agonist treated animals exhibited a less pronounced
immunopathology in the lung. Importantly, this applied exclu-
sively to histological parameters indicating immune-mediated
inflammation such as bronchointerstitial pneumonia, alveolar
infiltrations and the extent of lung tissue affected by the
inflammation (Figure 4), whereas no impact of ICOS agonist
treatment was detectable for bronchiolar and alveolar necrosis
which is largely induced by the pathogen itself.
Our finding that ICOS agonist treatment during the acute
phase of IAV infection improves immune-mediated pathology
prompted us to further investigate whether super-stimulation of
the ICOS signaling pathway would favor the induction of immune
regulatory mechanisms. Interestingly, we indeed observed a
significant increase in the frequency of Treg in BLN and spleen
on day 7 and 8 post infection, while the Treg level in the lung of
ICOS agonist treated mice was only slightly increased. Expansion
of Treg by targeted activation of the ICOS signaling pathway is
very well in line with previous reports demonstrating that ICOS is
required for the development of Treg [26], [31]. Very recently, it
has been shown that ICOS co-stimulation promotes the expansion
and maintenance of Foxp3+ Treg during helminthes infections
[42]. BALF concentration of the anti-inflammatory cytokine IL-10
was increased in the ICOS agonist group which is consistent with
reports showing the super-synthesis of IL-10 by ICOS-expressing
Tregs [43]. Based on published data [44] we hypothesized that
IFN-c induced in activated T cells in the context of ICOS
signaling would act in a paracrine manner on adjacent APCs
resulting in the production of IDO [45]. However, analysis of
serum and BALF activity of the immune regulatory enzyme IDO
revealed only marginal differences between the two experimental
groups with slightly higher IDO activity detectable in mice that
were treated with the ICOS agonist. The trend was similar to that
observed for IFN-c and IL-6 levels, but did, however, not reveal
significant differences. IL-10 and IDO are well known to create a
regulatory milieu and both mediators have been described to
inhibit the proliferation and differentiation of effector T cells [46–
48]. It may be speculated that an increased apoptosis induction in
CD8+ T cells following priming in the presence of ICOS agonist,
together with elevated concentrations of immunosuppressive
mediators, may account for the observed decline in CD8+ T cells
in the respiratory tract of IAV infected animals. Another
important fact to be considered in this context is that elevated
Treg numbers in the lymph nodes draining the site of acute virus
infections and in the spleen may negatively affect CD8+ T cell
priming [49], [50]. Although, partial depletion of CD25+ Treg has
been recently shown to have no effect on IAV induced mortality,
weight loss, viral clearance and cellularity within the lung [51], we
speculate that increased Treg levels in the BLN and spleen of ICOS
agonist treated mice may interfere with efficient priming of IAV-
specific CD8+ T cells. Inefficient CD8+ T cell priming combined
with an immunosuppressive milieu in the lung that has a negative
effect on the proliferation and effector cell differentiation would
result in reduced CD8 Teff cells with beneficial outcome for
immune-mediated influenza pneumonia. This is exactly what we
observe in mice treated with ICOS agonist during acute IAV
infection.
Previous investigations on the impact of ICOS signaling on the
course of infection and pathogen clearance had opposing outcome
dependent on the infection model used. Studies on the role of
ICOS in the control of systemic Salmonella typhimurium carried out
in ICOS2/2 mice supported the importance of ICOS for
immunoglobulin class switch and efficient induction of pathogen-
specific CD8+ T cell responses. In line with this, ICOS deficiency
resulted in delayed bacterial clearance [15] thus suggesting a
critical role of ICOS in the control of Salmonella infection.
Another study performed in ICOS2/2 mice addressed the impact
of ICOS on T cell responses and protection against Mycobacterium
tuberculosis (Mtb). In direct contrast to the Salmonella model, ICOS
deficient mice showed reduced Mtb bacterial burden in the
chronic phase of infection in the spleen (but not the lung) while
immunopathology was unaltered between knock out and wild type
mice [31]. Here, intriguingly and in support of our data, the
authors found that ICOS deficiency differentially affected CD4+
and CD8+ T cell subsets. In their model, the polyclonal CD4+ T
cell response against Mtb was improved which came along with
diminished frequencies of Tregs. Conclusively, while we demon-
strate the expansion of Treg following stimulation of the ICOS
signaling pathway in acute IAV infection, the opposite was found
in Mtb infection in mice lacking ICOS signaling. Interestingly,
Mtb infection in ICOS2/2 mice resulted in reduced numbers of
pathogen-specific CD8+ Teff cells and reduced CTL activity in the
chronic phase of infection [31], which was demonstrated also by us
when we stimulated ICOS signaling. Possible explanations for this
obvious discrepancy may be due to the fundamental differences in
the infection models used (viral versus bacterial, acute versus chronic,
local versus systemic) and that we analyzed the T cells much earlier,
i.e. already during the peak phase of adaptive immunity. Improved
Mtb clearance despite reduced CTL activity might most probably
account for the fact that unlike in IAV infection, Mtb clearance is
predominantly dependent on CD4+ T cells [52]. Next to bacterial
infections, the impact of ICOS signaling has also been studied for
viral pathogens including VSV, LCMV and IAV infection.
Depending on the viral pathogen analyzed, these studies also
revealed an important impact of ICOS signaling for the different
arms of adaptive immunity [32], [53]. Importantly, antibody-
mediated inhibition of ICOS during IAV infection resulted in
reduced CD8+ T cell numbers, pulmonary T cell-inflammation
and impaired control of IAV replication in the lung [30], thereby
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largely resembling the findings from our study. While the overall
outcome of ICOS inhibition and ICOS stimulation during acute
IAV infection appears to be similar, there may be considerable
differences in the underlying immunological mechanisms. Where-
as we found that ICOS super-activation predisposes CD8+ T cells
to apoptosis, ICOS inhibition did not enhance T cell apoptosis in
the lung. While our data suggest that ICOS stimulation expands
the Treg pool and that elevated Treg levels in combination with
increased IL-10 concentrations in the respiratory tract inhibits
CD8+ T cell priming and effector cell differentiation, Treg were not
analyzed in the study by Humphreys and colleagues. Taken
together, these mouse infection studies clearly indicate that ICOS
acts as important modulator of adaptive immune responses and
balances CD4+ Thelper, Treg and CD8
+ Teff cell responses, thereby
representing a potential target for the modulation of pathogen-
specific immunity.
In conclusion, to our knowledge, this is the first in-vivo study
addressing the specific impact of ICOS on the outcome of
infection utilizing ICOS activation rather than blocking. Super-
activation of ICOS during acute IAV infection was found to
modulate the respiratory and peripheral T cell pool resulting in an
increased Treg/CD8
+T cell ratio and delayed pathogen elimina-
tion from the lung. Attenuated antiviral immunity however
ameliorated immune-mediated influenza pneumonia making
ICOS an interesting target for therapeutic intervention in those
infectious conditions characterized by strong immuno-pathology
rather than virus-mediated cytopathic effects.
Supporting Information
Figure S1 Minor blockade of ICOS agonist binding to
activated T cells by soluble ICOS-L pre-incubation.
Splenic T cells were pre-activated in vitro with PHA and IL-2 for
72 hours followed by the addition of soluble ICOS-L B7h-Fc.
Control cells were not treated with B7h-Fc. After 30 minutes
incubation T cells were stained with the ICOS agonist antibody
C398.4A-FITC and binding of ICOS agonist to T cells in the
presence or absence of ICOS-L was analyzed by FACS. Left panel
shows representative histograms; right panel summarizes data as
mean fluorescence ratio (mean 6 SE) obtained from three
individual experiments.
(TIF)
Figure S2 In vivo treatment of mice with ICOS agonist
does not result in depletion of ICOS+ T cells. Mice were
treated with ICOS agonist (C398.4A) or hamster IgG as negative
control. After 72 hours mice were sacrificed and the proportion of
TCRab+ICOS+cells in the spleen was determined by FACS.
Shown are means 6 SE from three individual experiments.
(TIF)
Figure S3 Expression of ICOS on CD4+ and CD8+ T cells
at different time post influenza virus infection. Mice were
infected with a sublethal dose influenza A virus as described in
materials and methods. On day 1, 5, 7, 10 and 14 post infection
mice (n = 3) were sacrificed and the percentage of ICOS+ CD4+
and CD8+ T cells in bronchoalveaolar lavage fluid, lung, BLN and
spleen was determined by FACS analysis.
(TIF)
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